Trial · NCT05071209
Registered outcomes13
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 13 of 13
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Frequency of Cycle 1 Dose Limiting Toxicities for BAY 1895344 (Elimusertib) During Dose Escalation | Up to 28 days (cycle 1) | Frequency (%) of patients experiencing a cycle 1 dose limiting toxicity among toxicity-evaluable patients stratified by dose level during the dose escalation part of the study (Part A). |
| Primary | Response of BAY 1895344 (Elimusertib) | Through study completion, up to 37 months | Frequency (%) of patients with best response of complete response or partial response among response-evaluable patients stratified by Phase 2 cohort. |
| Secondary | Incidence of Adverse Events of BAY 1895344 (Elimusertib) | Through study completion, up to 37 months | Frequency (%) of patients with adverse events stratified by study part and dose level. |
| Secondary | Area Under the Drug Concentration Time Curve of BAY 1895344 (Elimusertib) | Up to 28 days | Median (min, max) of the area under the drug concentration time curve (AUC) in cycle 1 stratified by study part and dose level. |
| Secondary | Change in Phosphorylated (p)ATR of BAY 1895344 (Elimusertib) | Up to 28 days | Median (min, max) of the change in (p)ATR stratified by study part and dose level. |
| Secondary | Change in pH2AX of BAY 1895344 (Elimusertib) | Up to 28 days | Median (min, max) of the change in pH2AX stratified by study part and dose level. |
| Secondary | Change in pKAP1 of BAY 1895344 (Elimusertib) | Up to 28 days | Median (min, max) of the change in pKAP1 stratified by study part and dose level. |
| Secondary | Influence of ALT on Activity of BAY 1895344 | Up to 28 days | Median (min, max) of ALT in responders (CR or PR) versus non-responders among all response-evaluable patients. |
| Secondary | Influence of Tumor Tissue Expression of ATM on Activity of BAY 1895344 | Up to 28 days | Median (min, max) of ATM in responders (CR or PR) versus non-responders among all response-evaluable patients. |
| Secondary | Influence of Tumor Tissue Expression of PGBD5 on Activity of BAY 1895344 | Up to 28 days | Median (min, max) of PGBD5 in responders (CR or PR) versus non-responders among all response-evaluable patients. |
| Secondary | Influence of Tumor Tissue Expression of R-loops on Activity of BAY 1895344 | Up to 28 days | Median (min, max) of R-loops in responders (CR or PR) versus non-responders among all response-evaluable patients. |
| Secondary | Response of BAY 1895344 (Elimusertib) in Children < 18 Years | Up to 60 months | Frequency (%) of patients with best response of complete response or partial response among response-evaluable patients in the dose escalation part of the study (Part A). |
| Secondary | Response of BAY 1895344 in Pediatric Patients With Non-CNS Solid Tumors or Lymphomas | Up to 60 months | Frequency of patients with best response of complete response or partial response among response-evaluable patients with non-CNS solid tumors or lymphomas with specific deleterious alternations in DDR pathway. |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT05071209/registered